|
1
|
Mendenhall WM and Logan HL: Human
papillomavirus and head and neck cancer. Am J Clin Oncol.
32:535–539. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman
SM and Tsao AS: Meta-analysis of the impact of human papillomavirus
(HPV) on cancer risk and overall survival in head and neck squamous
cell carcinomas (HNSCC). Head Neck Oncol. 2:152010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fakhry C, Westra WH, Li S, Cmelak A, Ridge
JA, Pinto H, Forastiere A and Gillison ml: Improved survival of
patients with human papillomavirus-positive head and neck squamous
cell carcinoma in a prospective clinical trial. J Natl Cancer Inst.
100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sinha P, Logan HL and Mendenhall WM: Human
papillomavirus, smoking, and head and neck cancer. Am J
Otolaryngol. 33:130–136. 2012. View Article : Google Scholar
|
|
5
|
Nagadia R, Pandit P, Coman WB,
Cooper-White J and Punyadeera C: miRNAs in head and neck cancer
revisited. Cell Oncol. 36:1–7. 2013. View Article : Google Scholar
|
|
6
|
Michaud DS, Langevin SM, Eliot M, Nelson
HH, Pawlita M, McClean MD and Kelsey KT: High-risk HPV types and
head and neck cancer. Int J Cancer. 135:1653–1661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mendelsohn AH, Lai CK, Shintaku IP,
Elashoff DA, Dubinett SM, Abemayor E and St John MA:
Histopathologic findings of HPV and p16 positive HNSCC.
Laryngoscope. 120:1788–1794. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Benson E, Li R, Eisele D and Fakhry C: The
clinical impact of HPV tumor status upon head and neck squamous
cell carcinomas. Oral Oncol. 50:565–574. 2014. View Article : Google Scholar
|
|
9
|
Dok R and Nuyts S: HPV positive head and
neck cancers: Molecular pathogenesis and evolving treatment
strategies. Cancers. 8:E412016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grandis J: HER2 and HER3 in
HPV+ and HPV− HNSCC-Response. Clin Cancer
Res. 22:18262016. View Article : Google Scholar
|
|
11
|
Antonsson A, Neale RE, Boros S, Lampe G,
Coman WB, Pryor DI, Porceddu SV and Whiteman DC: Human
papillomavirus status and p16INK4A expression in
patients with mucosal squamous cell carcinoma of the head and neck
in Queensland, Australia. Cancer Epidemiol. 39:174–181. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tang J, Wang Z, Chen L, Huang G and Hu X:
Gossypol acetate induced apoptosis of pituitary tumor cells by
targeting the BCL-2 via the upregulated microRNA miR-15a. Int J
Clin Exp Med. 8:9079–9085. 2015.PubMed/NCBI
|
|
13
|
Lin K, Farahani M, Yang Y, Johnson GG,
Oates M, Atherton M, Douglas A, Kalakonda N and Pettitt AR: Loss of
MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA,
de-repression of BCL2 and adverse outcome in chronic lymphocytic
leukaemia. Br J Haematol. 167:346–355. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ricieri Brito JA, Gomes CC, Santos Pimenta
FJ, Barbosa AA, Prado MA, Prado VF, Gomez MV and Gomez RS: Reduced
expression of mir15a in the blood of patients with oral squamous
cell carcinoma is associated with tumor staging. Exp Ther Med.
1:217–221. 2010.PubMed/NCBI
|
|
15
|
Begum S, Cao D, Gillison M, Zahurak M and
Westra WH: Tissue distribution of human papillomavirus 16 DNA
integration in patients with tonsillar carcinoma. Clin Cancer Res.
11:5694–5699. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sivars L, Näsman A, Tertipis N, Vlastos A,
Ramqvist T, Dalianis T, Munck-Wikland E and Nordemar S: Human
papillomavirus and p53 expression in cancer of unknown primary in
the head and neck region in relation to clinical outcome. Cancer
Med. 3:376–384. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jakscha J, Zlobec I, Storck C, Obermann
EC, Tornillo L, Terracciano LM and Fischer CA: The clinical impact
of p16 status in fine-needle aspirates of cervical lymph node
metastasis of head and neck squamous cell carcinomas. Eur Arch
Otorhinolaryngol. 270:661–667. 2013. View Article : Google Scholar
|
|
18
|
Keller LM, Galloway TJ, Holdbrook T, Ruth
K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, et
al: p16 status, pathologic and clinical characteristics,
biomolecular signature, and long-term outcomes in head and neck
squamous cell carcinomas of unknown primary. Head Neck.
36:1677–1684. 2014. View Article : Google Scholar :
|
|
19
|
Tribius S, Hoffmann AS, Bastrop S, Görögh
T, Haag J, Röcken C, Clauditz T, Grob T, Wilczak W, Tennstedt P, et
al: HPV status in patients with head and neck of carcinoma of
unknown primary site: HPV, tobacco smoking, and outcome. Oral
Oncol. 48:1178–1184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fotopoulos G and Pavlidis N: The role of
human papilloma virus and p16 in occult primary of the head and
neck: A comprehensive review of the literature. Oral Oncol.
51:119–123. 2015. View Article : Google Scholar
|
|
21
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rautava J and Syrjänen S: Biology of human
papillomavirus infections in head and neck carcinogenesis. Head
Neck Pathol. 6(Suppl 1): S3–S15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jensen DH, Hedback N, Specht L, Høgdall E,
Andersen E, Therkildsen MH, Friis-Hansen L, Norrild B and von
Buchwald C: Human papillomavirus in head and neck squamous cell
carcinoma of unknown primary is a common event and a strong
predictor of survival. PLoS One. 9:e1104562014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu W, Feng L, Li P, Wang Y, Du Y, Chen X,
Wu S, Zhao G and Lou W: Effects of HPV-16 infection on
hypopharyngeal squamous cell carcinoma and FaDu cells. Oncol Rep.
35:99–106. 2016.
|
|
25
|
Westra WH: Detection of human
papillomavirus (HPV) in clinical samples: Evolving methods and
strategies for the accurate determination of HPV status of head and
neck carcinomas. Oral Oncol. 50:771–779. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee HW, Lee SS, Lee SJ and Um HD: Bcl-w is
expressed in a majority of infiltrative gastric adenocarcinomas and
suppresses the cancer cell death by blocking stress-activated
protein kinase/c-Jun NH2-terminal kinase activation. Cancer Res.
63:1093–1100. 2003.PubMed/NCBI
|
|
27
|
Qu J, Zhao L, Zhang P, Wang J, Xu N, Mi W,
Jiang X, Zhang C and Qu J: MicroRNA-195 chemosensitizes colon
cancer cells to the chemotherapeutic drug doxorubicin by targeting
the first binding site of BCL2L2 mRNA. J Cell Physiol. 230:535–545.
2015. View Article : Google Scholar
|
|
28
|
Wang F, Liu M, Li X and Tang H: MiR-214
reduces cell survival and enhances cisplatin-induced cytotoxicity
via down-regulation of Bcl2l2 in cervical cancer cells. FEBS Lett.
587:488–495. 2013. View Article : Google Scholar : PubMed/NCBI
|
